Physician profile
William C Sim
NPI 1437256906
$9,649.85
in general payments reported to CMS, 2019-2025
60 companies · $1,982 in 2025
The $1,982 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $718 · 2020: $1,043 · 2021: $1,687 · 2022: $1,058 · 2023: $1,273 · 2024: $1,889 · 2025: $1,982.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,144.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,399.18 | 2020-2025 | Ubrelvy, Qulipta, Synthroid |
| Lilly USA, LLC | $1,055.22 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $935.78 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $734.56 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $517.51 | 2019-2025 | Jardiance, Ofev |
| Novo Nordisk INC | $491.78 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Merck Sharp & Dohme LLC | $466.78 | 2019-2025 | Capvaxive |
| Pfizer INC. | $416.03 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $313.10 | 2021-2025 | |
| Amarin Pharma, INC. | $299.52 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $271.39 | 2019-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $260.58 | 2023-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $229.80 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $153.32 | 2024-2025 | Voquezna |
| Amgen INC. | $135.56 | 2019-2025 | Repatha, Krystexxa, Repatha |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Sim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.